En nyligt rapporteret interaktion med stoffet repaglinid er blevet føjet til kontraindikationerne.
The risk of muscle disorders (myopathy/ rhabdomyolysis) and the special warnings and special precautions for use in case of concomitant administration of HMG CoA reductase inhibitors were further emphasised in the harmonised SPC.